The ouster of Sarepta Therapeutics Inc. CEO Chris Garabedian and his temporary replacement by Chief Medical Officer Edward Kaye is intended to smooth the development and regulatory path forward for the company’s Duchenne muscular dystrophy treatment eteplirsen.
Kaye and interim chairman John Hodgman attempted to be diplomatic in their comments about the changeover at the Cambridge, Mass.-based...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?